Could a Two-Drug pill replace triple therapy for kids with HIV?
NCT ID NCT04337450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a two-drug combination (dolutegravir and lamivudine) is as safe and effective as the standard three-drug HIV treatment for children aged 2 to 15. About 386 children who already have undetectable HIV levels will take either the two-drug pill or their usual three-drug regimen. The goal is to see if the simpler treatment can keep the virus suppressed for up to 96 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dolutegravir and lamivudine (two anti-HIV medicines)
What this could lead to
If successful, this could offer a simpler, two-drug daily pill for children with HIV, reducing side effects and treatment burden while maintaining viral suppression.
What could go wrong
This is a mid-stage trial with 386 children, so results may not apply to all. There is a risk that the two-drug combo may not suppress the virus as well as three-drug regimens, leading to viral rebound.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor
Kampala, Uganda
-
Birmingham Heartlands Hospital
Birmingham, United Kingdom
-
Chiangrai Prachanukroh Hospital
Chiang Rai, Thailand
-
Great Ormand Street Hospital
London, United Kingdom
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Joint Clinical Research Centre
Kampala, Uganda
-
Khon Kaen Hospital
Khon Kaen, Thailand
-
King Edward VIII Hospital
Durban, South Africa
-
MUJHU
Kampala, Uganda
-
Nakornping Hospital
Chiang Mai, Thailand
-
PHRU
Soweto, South Africa
-
PHRU Klerksdorp
Klerksdorp, South Africa
-
Prapokklao Hospital
Chanthaburi, Thailand
-
St. Mary's Hospital
London, United Kingdom